WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36 th Annual Healthcare Conference in New York, NY on December 3 at 1:00... Read More

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at... Read More

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into... Read More

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases Phase 1 healthy volunteer data expected to be reported in the first half of 2025 WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Kymera... Read More

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. To access the October 31 conference call via phone, please dial +1 (833)... Read More

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer... Read More

KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein... Read More

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with the potential to alleviate these symptoms in atopic dermatitis patients KT-621 expected to start Phase 1 in the second half of... Read More

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at... Read More

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to... Read More

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares... Read More

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to... Read More

Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 (STAT3) oncology degrader... Read More

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET. To access the August 7 conference call via phone, please dial +1 (833) 630-2127... Read More

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be available under “ News... Read More

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it intends to expand the ongoing... Read More

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) --... Read More

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule... Read More

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET;... Read More

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule... Read More

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22,... Read More

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage... Read More

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT;... Read More

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively... Read More

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET. To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or... Read More

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing... Read More

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc . (NASDAQ: KYMR), a clinical-stage biopharmaceutical company... Read More

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 44 th Annual Healthcare Conference in Boston, MA on March 6 at 12:50 p.m. ET;... Read More

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 Additional KT-333 (STAT3) and KT-253 (MDM2) Phase 1 data expected in 2024 Well-capitalized with $745 million 1 in cash as of January 9, 2024, and runway into the... Read More

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET. To access the February 22 conference call via phone, please dial... Read More

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6 th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET. A live webcast of the... Read More

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025 STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter... Read More

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to... Read More

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares... Read More

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to... Read More

Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter Phase 1 clinical trial in the... Read More

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi,... Read More

WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company’s emerging... Read More

STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect demonstrated in tumor as well as blood KT-333 was generally well-tolerated with dose escalation continuing WATERTOWN, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.... Read More

Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS) Topline Phase 2 data from both the AD and HS trials expected in the first half of 2025 WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule... Read More

KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients Trial showed encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), with a systemic anti-inflammatory effect observed in patients with moderate-to-severe disease Study is first published clinical trial using a heterobifunctional... Read More

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH) 65 th Annual Meeting and Exposition on December 10, 2023 WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small... Read More

First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to be released today highlights KT-333 (STAT3) safety, PK/PD and initial anti-tumor activity in Phase 1 clinical trial KT-253 (MDM2) degrader achieved clinical proof-of-mechanism in Phase 1... Read More

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events: TD Cowen 7 th Annual Virtual Fall Oncology Innovation Summit on November 3 at 2:00 p.m. ET; UBS Biopharma... Read More

WATERTOWN, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4... Read More

WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day. To access the November 2 conference call via phone, please dial +1 (833)... Read More

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to be highly active compared to MDM2 small molecule inhibitor in preclinical models of Merkel cell carcinoma (MCC) WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage... Read More

KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development path for the treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a... Read More

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team will attend and participate in presentations at the following upcoming investor events: Wells Fargo 2023 Healthcare Conference in Boston, MA... Read More

KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 (MDM2), KT-333 (STAT3), and KT-413 (IRAKIMiD) degraders ongoing, with clinical updates planned for later in 2023 June 30, 2023 cash balance approximately $472 million, with cash runway into second half of 2025 Company to hold quarterly results... Read More

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on August 3, 2023, and will host a conference call at 8:30 a.m. ET that day. To access the August 3 conference call via phone, please dial +1... Read More

WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML). KT-253 is a highly potent and... Read More

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models No dose limiting toxicities observed in either program KT-333 data will be presented in a poster session at the International Conference on Malignant Lymphoma (ICML) on June 16 WATERTOWN, Mass., June 14, 2023 (GLOBE... Read More

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose limiting toxicities observed Data on additional KT-333 and KT-413 patient cohorts to be shared in conjunction with next week’s ICML meeting WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:... Read More

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, will present preclinical data on KT-253, a potent and selective heterobifunctional MDM2 degrader. The data will be presented at the European Hematology Association (EHA) Congress, taking... Read More

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team will attend the following upcoming investor event: Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 14 at... Read More

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. Dr. Chadwick joins Kymera with extensive experience overseeing global development operations,... Read More

KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of liquid and solid tumors Company plans to share initial safety and proof-of-mechanism clinical data in second half of 2023 WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage... Read More

In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients and was generally well-tolerated Clinical endpoints addressing disease burden and symptoms demonstrated a highly competitive profile with substantial responses in the majority of both HS and AD patients with... Read More

Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023; Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing, with program updates at ICML in June March 31, 2023 cash balance approximately $516 million, with cash runway into second half of 2025 Company to hold quarterly results call at... Read More

WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report first quarter 2023 financial results on May 4, 2023, and will host a conference call at 8:30 a.m. ET that day. Kymera Therapeutics also announced the Company’s management team... Read More

WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team will attend the following upcoming investor events: Cowen 43 rd Annual Health Care Conference in Boston, MA on March 6-8, 2023; Nello... Read More

Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing, with data evaluating clinical activity expected to be shared in 2023 Phase 1 clinical trial for MDM2 degrader (KT-253) expected to be initiated in early 2023 Year-end 2022 cash balance of approximately $560 million with cash runway into second half of 2025... Read More

WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report fourth quarter and full year 2022 financial results on February 23, 2023, and will host a conference call at 8:30 a.m. ET that day. Kymera Therapeutics also announced the Company’s... Read More

WALTHAM, Mass. / Jan 31, 2023 / Business Wire / X -Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X-Chem applying its world-leading DEL platform to... Read More

WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023. “2022 was a pivotal year for Kymera, as the Phase 1 trial of our lead program, KT-474 (SAR444656), demonstrated... Read More

WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Chiniara joins Kymera with extensive experience overseeing legal activities... Read More

WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 9:00 AM PST. Nello Mainolfi, PhD,... Read More

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile Clinical endpoints addressing disease burden and symptoms demonstrate a highly competitive profile after four weeks of dosing, with substantial responses in majority of both HS and AD patients Modest,... Read More

Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies Preclinical study highlights the potential of IRAKIMiDs combined with BCL-2 inhibitor as a therapeutic approach for the treatment of MYD88-mutant diffuse large B-cell lymphoma (DLBCL) WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE)... Read More

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of venetoclax-resistant AML KT-253 also active in other hematologic malignancies including DLBCL WATERTOWN, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report third quarter 2022 financial results on November 3, 2022 and will host a conference call at 8:30 a.m. ET that day. Kymera Therapeutics also announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in... Read More

Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalation KT-253 has completed IND enabling studies Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will hold an investor webcast on December 14 to present clinical data from the... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). KT-333 is a first-in-class degrader of the transcriptional regulator STAT3.... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference: September 7th at 1:20 p.m. ET Morgan Stanley 20th... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 2,769,228 shares of its common stock (“Common Stock”) at a price of $26.00 per share and pre-funded warrants... Read More

Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs, initial data to be shared by year end June 30, 2022 cash balance of $482.5 million, providing cash runway into 2025 Company to hold quarterly results call at 8:30 a.m. EST (877-317-6789 or +1 412-317-6789) Kymera... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on August 9, 2022 and will host a conference call at 8:30 a.m. ET that day. To access the conference call via phone, please dial 877-317-6789 (U.S.) or +1-412-317-6789 (International) and ask to... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera’s Board as a senior executive accomplished in scaling global, profitable, high-performing organizations. “Leigh has distinguished herself as an... Read More

KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and solid tumors KT-413 is a first-in-class degrader of IRAK4 and the IMiD substrates Ikaros and Aiolos in development for MYD88-mutant B cell lymphomas Initial safety and proof-of-mechanism clinical data for both programs to be shared in second half of 2022 Kymera Therapeutics, Inc. (NASDAQ:... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL). KT-333 is a first-in-class degrader of the transcriptional regulator STAT3.... Read More

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis (CIA), a pre-clinical model of rheumatoid arthritis, today at the EULAR 2022 Congress... Read More

Kymera Therapeutics, Inc . (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022,... Read More

Data to be shared at the American Association of Immunologists (AAI) Annual Meeting Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors Findings support further exploration of STAT3 degraders in Th17-driven autoimmune indications Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company... Read More

IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader... Read More